# A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

> **NCT01920061** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 110 (actual)

## Conditions studied

- Neoplasm

## Interventions

- **DRUG:** PF-05212384 (gedatolisib)
- **DRUG:** Docetaxel
- **DRUG:** Cisplatin
- **DRUG:** Dacomitinib

## Key facts

- **NCT ID:** NCT01920061
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-10
- **Primary completion:** 2020-01-08
- **Final completion:** 2020-01-08
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2022-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01920061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01920061, "A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01920061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*